Ceptyr

About Ceptyr

Ceptyr Inc. is a biopharmaceutical company specializing in the discovery and development of small molecule pharmaceuticals. The company initiated its operations in December 1995, originally under the name Charybdis Corp., before rebranding. The firm was co-founded by Nick Tonks, who serves as the Chief Scientific Officer, with Williams S. Ettouati acting as President and CEO.

The company's strategic focus is centered on leveraging its deep understanding of protein tyrosine phosphatases (PTPs) as viable targets for therapeutic intervention. Ceptyr's drug discovery pipeline targets a range of significant health issues, including immunosuppression, type II diabetes, obesity, and oncology. The business model is predicated on the research and development of novel drug candidates, with the ultimate goal of commercialization. This approach is typical of a technology platform-based biotech firm, which aims to create value by developing a portfolio of potential therapeutic products derived from its core scientific expertise.

To execute its strategy, Ceptyr has developed a proprietary technology platform for drug discovery. This platform incorporates high-throughput screening assays alongside biochemical and cell-based assays to effectively identify and select promising compounds for further development. This systematic process has enabled the company to identify several lead candidate compounds, particularly in the fields of immunosuppression and type II diabetes. A significant milestone was achieved in August 1999 when the company secured approximately $11.5 million in a Series C equity investment round, bringing its total raised equity capital to $16.1 million. This funding was earmarked to accelerate the drug discovery programs and expand the management and scientific teams.